Quick Answer
Aprea Therapeutics, Inc. reported Diluted EPS of $1.93 per share (loss) for fiscal year 2025.
Aprea Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.93 | +17.9% |
| 2024 | -$2.35 | +40.5% |
| 2023 | -$3.95 | +94.2% |
| 2022 | -$67.99 | -94.9% |
| 2021 | -$34.88 | +31.1% |
| 2020 | -$50.61 | -983.7% |
| 2019 | -$4.67 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.47 | +26.6% | +11.3% |
| June 30, 2025 | -$0.53 | +8.6% | +19.7% |
| March 31, 2025 | -$0.66 | +1.5% | -3.1% |
| September 30, 2024 | -$0.64 | +25.6% | -10.3% |
| June 30, 2024 | -$0.58 | +33.3% | +13.4% |
| March 31, 2024 | -$0.67 | +50.0% | +22.1% |
| September 30, 2023 | -$0.86 | +62.9% | +1.1% |
| June 30, 2023 | -$0.87 | +99.0% | +35.1% |
- Aprea Therapeutics, Inc. showed an increase of +17.9% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2025 period, Aprea Therapeutics, Inc.’s diluted eps has grown by 58.7% (from $4.67 per share (loss) to $1.93 per share (loss)).
- The most recent figure is from Aprea Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: